ADIPOQ and metabolic dysfunction-associated steatohepatitis: Dose–response higher proportion of fibrosis improvement without worsening of MASH (39 and 48% vs. 29% for placebo), and of MASH resolution without worsening fibrosis (25 and 36% vs. 7% for placebo)Increase in adiponectin despite weight gain